Skip to content

Study · Measured the body's own peptide · 1994

3 results

Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats.

Li Q, Brownfield MS, Levy AD, Battaglia G, Cabrera TM, Van de Kar LD

Biological psychiatry1 Sept 1994Cited by 38 (Europe PMC)

PMID7993956 (opens in a new tab)DOI10.1016/0006-3223(94)90627-0 (opens in a new tab)PepBankPUB-07993956
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In male rats, ipsapirone increased plasma oxytocin concentrations.

    In plain wordsIn male rats, the drug ipsapirone raised the body's own oxytocin level in blood.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin after ipsapirone
    Study

    ratn: not reported in source

    male rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Ipsapirone increased oxytocin, adrenocorticotropic hormone (ACTH), corticosterone, and prolactin
    1 context sentence
    Summary · context
    We determined the effect of chronic fluoxetine and desipramine (DMI) on the hormone response to ipsapirone, a 5-HT1A agonist and a potential anxiolytic drug.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Other

    In male rats, chronic fluoxetine significantly inhibited the ipsapirone-induced rise in plasma oxytocin.

    In plain wordsIn male rats, long-term fluoxetine reduced the rise in the body's own oxytocin level caused by ipsapirone.

    Peptide
    Oxytocin
    Outcome
    DecreaseIpsapirone-induced plasma oxytocin rise after chronic fluoxetine
    Study

    ratn: not reported in source

    male rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Chronic fluoxetine, but not DMI, significantly inhibited the effect of ipsapirone on plasma oxytocin
    1 context sentence
    Summary · context
    We determined the effect of chronic fluoxetine and desipramine (DMI) on the hormone response to ipsapirone, a 5-HT1A agonist and a potential anxiolytic drug.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Other

    In male rats, chronic desipramine did not significantly inhibit the ipsapirone-induced rise in plasma oxytocin.

    In plain wordsIn male rats, long-term desipramine did not reduce the rise in the body's own oxytocin level caused by ipsapirone.

    Peptide
    Oxytocin
    Outcome
    No significant changeIpsapirone-induced plasma oxytocin rise after chronic desipramine
    Study

    ratn: not reported in source

    male rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Chronic fluoxetine, but not DMI, significantly inhibited the effect of ipsapirone on plasma oxytocin, ACTH and corticosterone concentrations.
    1 context sentence
    Summary · context
    We determined the effect of chronic fluoxetine and desipramine (DMI) on the hormone response to ipsapirone, a 5-HT1A agonist and a potential anxiolytic drug.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:52 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.